-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) issued an announcement. Recently, the company and Menarini reached an exclusive license agreement to grant Menarini the right to market, register and commercialize the bovenglutide overweight or obesity indication program independently developed by the company within the authorized region. The company licensed the exclusive rights to develop and commercialize boflavin in 27 EU member states and 39 European countries and regions, including the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, and the Balkans, to Menarini for a fee.

Zhitongcaijing·08/10/2026 10:01:07
Listen to the news
Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) issued an announcement. Recently, the company and Menarini reached an exclusive license agreement to grant Menarini the right to market, register and commercialize the bovenglutide overweight or obesity indication program independently developed by the company within the authorized region. The company licensed the exclusive rights to develop and commercialize boflavin in 27 EU member states and 39 European countries and regions, including the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, and the Balkans, to Menarini for a fee.